Bioequivalence Study Comparing the Pharmacokinetics and Glucodynamics of LY900014 U-200 Formulation With LY900014 U-100 Formulation in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Insulin lispro (Primary)
- Indications Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 19 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018.
- 05 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018.